Agilent Technologies
A
$114.42
-5.02%
Agilent Technologies Inc. is a leading life sciences and diagnostics company that provides measurement technologies and solutions across three core segments: life sciences and diagnostics, cross lab operations (consumables and services), and applied end markets. The company is a well-established market leader with a distinct competitive identity rooted in its heritage as a spin-off from Hewlett-Packard, serving a diverse and sticky customer base in biopharmaceuticals, chemicals, and advanced materials. The current investor narrative is shaped by its strategic acquisition of Biocare Medical to accelerate growth in the high-margin pathology market, while the broader debate centers on the company's ability to navigate a challenging macro environment for life sciences tools, as evidenced by recent revenue trends and stock price performance.…
A
Agilent Technologies
$114.42
Related headlines
Investment Opinion: Should I buy A Today?
Rating & Thesis: Hold. Agilent is a high-quality company caught in a cyclical slowdown; the current price reflects known challenges, but catalysts for a re-rating are not yet visible. This aligns with the limited but bullish analyst sentiment (Overweight/Buy ratings from major firms).
Supporting Evidence: The recommendation is supported by four key data points: 1) The forward PE of 18.52x offers a reasonable entry point for a company with a 19.33% ROE. 2) Revenue, while decelerating, is still growing at nearly 7% YoY. 3) Profitability remains intact with a net margin of 16.96% and a robust gross margin of 52.61%. 4) The strong balance sheet (D/E 0.50) and $993M in TTM FCF provide a margin of safety and capacity for shareholder returns or strategic M&A.
Risks & Conditions: The two biggest risks are further margin erosion and a failure of the Biocare acquisition to accelerate growth. This Hold would upgrade to a Buy if the forward PE compresses further toward 15x on sustained earnings, or if quarterly revenue growth re-accelerates above 10% with stable margins. It would downgrade to a Sell if net margins fall below 15% or if the stock breaks decisively below the $99 support level. The stock is currently fairly valued relative to its near-term challenged growth profile but undervalued on a longer-term normalized earnings basis.
Sign up to view all
A 12-Month Price Forecast
The outlook for Agilent is one of stabilization after a significant correction. The bear case of further deterioration is possible but mitigated by the company's quality and balance sheet. The bull case requires a swift macro recovery and flawless M&A execution, which carries lower odds in the near term. The base case of muddling through with modest growth is most probable. The stance would upgrade to bullish on evidence of margin stabilization in the next quarter or a drop toward the $110 support level, enhancing the risk/reward. It would turn bearish on a breakdown below $99.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Agilent Technologies's 12-month outlook, with a consensus price target around $148.75 and implied upside of +30.0% versus the current price.
Average Target
$148.75
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$92 - $149
Analyst target range
Analyst coverage for Agilent is limited, with only 5 analysts providing estimates, which is relatively low for a company of its size and suggests it may be under-followed by the broader institutional community, potentially leading to higher volatility. The consensus sentiment leans bullish, as evidenced by recent institutional ratings from firms like Morgan Stanley, Barclays, and UBS maintaining 'Overweight' or 'Buy' ratings, with an upgrade from Evercore ISI Group to 'Outperform' in January 2026. The average target price is not explicitly provided in the data, but analyst estimates point to an average EPS forecast of $8.61 for the coming year, with a tight range between $8.50 and $8.70, indicating strong conviction in near-term earnings stability; however, without a specific price target, the implied upside cannot be calculated, and the narrow EPS range contrasts with the stock's high volatility, highlighting a disconnect between analyst earnings certainty and market price uncertainty.
Bulls vs Bears: A Investment Factors
The evidence currently tilts bearish, as fundamental deceleration in revenue growth and, more critically, a 30% sequential drop in net income are concrete negatives that outweigh the bullish arguments of valuation discount and financial strength. The most important tension in the investment debate is whether the significant compression in forward valuation (18.52x PE) adequately prices in the ongoing earnings slowdown and macro headwinds, or if further estimate cuts are needed. The resolution of this tension—specifically, whether Q1 2026 margins represent a trough or a new normal—will determine the stock's direction.
Bullish
- Strong Forward PE Discount: The forward PE of 18.52x is a significant 42% discount to the trailing PE of 31.79x, indicating the market has priced in a substantial earnings recovery. This forward multiple is reasonable for a company with a stable 19.33% ROE and robust free cash flow of $993M.
- High-Quality, Sticky Customer Base: Over half of sales come from biopharmaceutical, chemical, and advanced materials end markets, which are considered sticky and provide recurring revenue. This is supported by a large, services-focused CrossLab segment ($758M in Q1 2026), contributing to stable cash flows.
- Robust Balance Sheet & Cash Flow: The company has a strong financial position with a debt-to-equity ratio of 0.50, a current ratio of 1.96, and trailing free cash flow of $993M. This provides ample liquidity to fund strategic acquisitions like Biocare Medical and navigate macro headwinds.
- Analyst Conviction in Earnings Stability: Despite limited coverage, the 5 analysts show strong conviction with a tight EPS forecast range of $8.50-$8.70 for the coming year, averaging $8.61. This narrow range suggests confidence in the company's near-term earnings power despite market volatility.
Bearish
- Severe Revenue & Profit Deceleration: Q1 2026 revenue growth slowed to 6.96% YoY from $1.798B, a deceleration from prior quarters. More critically, net income fell 30% sequentially to $305M, and the net margin compressed to 16.96% from 23.32% in Q4 2025.
- Persistent Underperformance vs. Market: The stock has significantly underperformed the S&P 500, down 14.13% over six months and 12.73% over three months, while the index gained. Its 1-year relative strength of -15.98% confirms a sustained period of weakness and negative investor sentiment.
- Elevated Valuation Despite Slowdown: Even after the sell-off, the trailing PE of 31.79x and PS ratio of 5.96x remain elevated, especially in the context of decelerating growth. The PEG ratio of 9.41 is extremely high, indicating the stock is expensive relative to its growth profile.
- High Volatility & Substantial Drawdown Risk: With a beta of 1.30, the stock is 30% more volatile than the market. It has already experienced a maximum drawdown of -29.87%, and a break below the $99.12 support could trigger further significant losses.
A Technical Analysis
The stock is in a pronounced downtrend, having declined 14.13% over the past six months and 12.73% over the past three months, significantly underperforming the S&P 500, which gained 6.89% and 2.67% over the same periods, respectively. Currently trading at $121.87, the price sits at approximately 48% of its 52-week range ($99.12 to $160.27), indicating it is much closer to its 52-week low than its high, which may signal a potential value opportunity but also reflects substantial negative momentum and investor pessimism. Recent momentum shows a short-term rebound, with the stock up 9.30% over the past month, which diverges positively from the longer-term downtrend and could signal a potential stabilization or mean reversion attempt, though its 1-year relative strength of -15.98% versus the S&P 500 underscores persistent weakness. Key technical support is clearly defined at the 52-week low of $99.12, while resistance lies at the 52-week high of $160.27; a sustained breakdown below support would signal a continuation of the bearish trend, whereas a move above recent highs near $150 would be needed to suggest a trend reversal. The stock's beta of 1.30 indicates it is approximately 30% more volatile than the broader market, which is an important consideration for risk management given its current elevated volatility and 29.87% maximum drawdown.
Beta
1.30
1.30x market volatility
Max Drawdown
-29.9%
Largest decline past year
52-Week Range
$103-$160
Price range past year
Annual Return
+9.0%
Cumulative gain past year
| Period | A Return | S&P 500 |
|---|---|---|
| 1m | +0.2% | +8.5% |
| 3m | -15.3% | +2.8% |
| 6m | -22.7% | +4.6% |
| 1y | +9.0% | +32.3% |
| ytd | -17.1% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
A Fundamental Analysis
Revenue growth has decelerated, with the most recent quarterly revenue of $1.798 billion representing a year-over-year increase of 6.96%, a slowdown from the stronger growth seen in prior quarters like Q4 2025's $1.861 billion. The revenue segment data for Q1 2026 shows Agilent CrossLab ($758M), Life Sciences and Applied Markets ($679M), and Applied Markets ($361M), indicating the services-focused CrossLab segment is the largest contributor, though growth trends across segments are not detailed in the provided data. Profitability remains intact but has moderated, with net income of $305 million in Q1 2026 and a net margin of 16.96%, down from the prior quarter's net income of $434 million and margin of 23.32%; gross margin was stable at 52.61%, which is healthy for the industry, but operating margin compressed to 19.63% from 23.80% in the previous quarter. The balance sheet and cash flow position remain strong, with a debt-to-equity ratio of 0.50 indicating moderate leverage, a robust current ratio of 1.96 for liquidity, and trailing twelve-month free cash flow of $993 million providing ample internal funding capacity; the return on equity of 19.33% demonstrates efficient use of shareholder capital.
Quarterly Revenue
$1.8B
2026-01
Revenue YoY Growth
+0.06%
YoY Comparison
Gross Margin
+0.52%
Latest Quarter
Free Cash Flow
$993000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is A Overvalued?
Given the company's positive net income of $305 million in the last quarter, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio stands at 31.79x, while the forward PE is notably lower at 18.52x, implying the market expects a significant earnings recovery or growth acceleration in the coming year. Compared to sector averages, Agilent's trailing PE of 31.79x and Price-to-Sales (PS) ratio of 5.96x are not directly benchmarked against provided industry averages, but the forward PE discount to its own trailing multiple suggests the market has already priced in near-term earnings challenges. Historically, the stock's current trailing PE of 31.79x is below its own recent historical highs seen in early 2025 (e.g., 35.66x in Q2 2025) but above the lower end of its range observed in late 2024 (26.92x in Q4 2024), positioning it in the mid-to-upper range of its own historical band, which suggests expectations are not at peak optimism but also not pricing in deep distress.
PE
31.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 16x~81x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary risk is earnings volatility and margin pressure, as evidenced by the 30% sequential drop in net income and a 360 basis point compression in net margin from Q4 2025 to Q1 2026. While the balance sheet is strong (D/E 0.50), the company's valuation (31.79x trailing PE) remains dependent on a return to higher growth rates. Revenue concentration in cyclical end-markets like biopharma and chemicals exposes the company to capital expenditure pullbacks from customers, which may be driving the current 6.96% YoY revenue growth deceleration.
Market & Competitive Risks: The stock faces significant valuation compression risk, trading at a trailing PE of 31.79x and a PS of 5.96x while growth is slowing. Its high beta of 1.30 makes it susceptible to broader market sell-offs, especially if sector rotation away from growth or healthcare occurs. Competitive and integration risks are present, as the recent Biocare Medical acquisition must be executed flawlessly to boost growth in the pathology market without diluting the currently healthy 52.61% gross margin.
Worst-Case Scenario: A continuation of the current downtrend, fueled by another quarter of margin compression and guidance reduction, could lead to a full retest of the 52-week low of $99.12. This scenario would likely be triggered by persistent macro weakness in life sciences tool spending and a failed integration of the Biocare acquisition. From the current price of $121.87, this represents a realistic downside of approximately -19%. A break below this support could trigger a steeper decline towards the $90 level, aligning with a historical max drawdown exceeding -29%.
FAQ
The key risks are, in order of severity: 1) Financial/Operational Risk: Continued earnings and margin compression, as seen in Q1 2026 with a 30% drop in net income. 2) Market/Valuation Risk: High volatility (beta 1.30) and potential for further multiple contraction if growth disappoints, with a recent max drawdown of -29.87%. 3) Macro Risk: Sensitivity to capital spending cycles in its core biopharma and chemical end markets, which is driving the current revenue deceleration. 4) Integration Risk: The Biocare Medical acquisition failing to deliver expected growth or synergies, diluting shareholder value.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $125 and $140, assuming the company meets current analyst EPS estimates of ~$8.61 and growth stabilizes. The Bull Case (25% probability) targets $150 to $160, requiring a successful acquisition integration and a macro recovery. The Bear Case (15% probability) warns of a drop to $99-$115 if margins deteriorate further and support breaks. The base case is most likely, hinging on the assumption that Q1 2026 represented a cyclical trough, not a new normal.
Agilent's valuation presents a mixed picture. On a trailing basis, it appears expensive with a PE of 31.79x and a PS of 5.96x, especially given decelerating growth. However, the forward PE of 18.52x suggests the market expects significant earnings recovery and offers a more compelling value. Compared to its own historical range, the current trailing PE is in the mid-to-upper band. Overall, the stock is fairly valued relative to its near-term challenged fundamentals but could be considered undervalued if one has high conviction in a 2027 earnings rebound. The market is currently pricing in a slowdown but not a collapse.
Agilent (A) is a conditional buy for patient, value-oriented investors. The forward PE of 18.5x is reasonable for a company of its quality, and the stock is trading near the lower end of its 52-week range, suggesting much bad news is priced in. However, with revenue growth slowing to 6.96% and net income down 30% sequentially, it is not a low-risk purchase. It is a good buy for those who believe the current slowdown is cyclical and temporary, and who are willing to withstand potential volatility (beta 1.30) for a long-term holding. A more attractive entry point might emerge if the stock tests support near $110.
Agilent is primarily suitable for a long-term investment horizon of 3-5 years. Its business model benefits from long-term secular trends in life sciences, but it is currently in a cyclical downturn that may take several quarters to work through. The stock's high beta (1.30) and lack of a significant dividend (yield 0.68%) make it less ideal for short-term trading or income-seeking investors. A long-term horizon allows investors to look through the current volatility, benefit from the company's strategic acquisitions, and wait for the earnings cycle to turn positive. A minimum holding period of 18-24 months is suggested to validate the turnaround thesis.
